Curetis eyes IPO on Euronext

The company is also backed by Aeris Capital, Forbion, HBM Partners, BioMed Partners, Roche Venture Fund, Qiagen, CD-Venture and KfW.

Curetis's current shareholders intend to subscribe for shares amounting to €15m. A date for the flotation was not yet been set. 

The offering will consist of newly issued shares through a public offering to retail and institutional investors in Germany and a private placement to investors in other countries.

The company plans to use the proceeds from the IPO for further international expansion to Asian countries such as Indonesia, Malaysia, Singapore, Thailand and China, as well as the US. The countries outside of Germany it currently operates in are Kuwait, Qatar, Russia and the United Arab Emirates.

In November 2014, Life Sciences Partners' Health Economics Fund (LSP-HEF) co-led a €14.5m series-B extension for medical diagnostics company Curetis. Molecular diagnostics technology business Qiagen was the other lead investor in the round. The extension brought the total capital raised by the company to €63.5m.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Benelux
• Healthcare
• Exits
• Germany
• IPO
• Netherlands
• Belgium